Traders Purchase High Volume of Definium Therapeutics Call Options (NASDAQ:DFTX)

Key Points

• Unusual options activity: Investors purchased 16,346 Definium Therapeutics call options, about 342% above the average volume of 3,697 contracts, suggesting heightened bullish interest.
• Analysts remain optimistic: The stock has a consensus “Buy” rating and a $63 price target, with several firms recently raising their targets to between $60 and $75.
• Mixed company signals: DFTX fell 3.1% to $44.42 and recently missed quarterly earnings estimates, while insiders have sold $2.17 million of stock over the past 90 days.

Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) was the target of some unusual options trading activity on Thursday. Investors acquired 16,346 call options on the stock. This is an increase of approximately 342% compared to the average volume of 3,697 call options.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Needham & Company LLC boosted their target price on Definium Therapeutics from $50.00 to $66.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. Stifel Nicolaus increased their price target on Definium Therapeutics from $30.00 to $60.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. Piper Sandler reissued an "overweight" rating and set a $75.00 price target (up from $73.00) on shares of Definium Therapeutics in a research note on Friday, August 7th. Wells Fargo & Company boosted their price objective on Definium Therapeutics from $68.00 to $72.00 and gave the company an "overweight" rating in a report on Thursday, August 13th. Finally, Leerink Partners set a $52.00 price objective on Definium Therapeutics and gave the company an "outperform" rating in a research report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Definium Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $63.00.

Insider Activity

In other news, insider Mark Sullivan sold 13,008 shares of the firm's stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the sale, the insider owned 320,571 shares in the company, valued at approximately $14,435,312.13. This trade represents a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Matthew T. Wiley sold 2,867 shares of Definium Therapeutics stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $129,101.01. Following the transaction, the insider directly owned 174,633 shares of the company's stock, valued at approximately $7,863,723.99. This represents a 1.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 48,096 shares of company stock worth $2,165,763. Insiders own 2.40% of the company's stock.

Institutional Investors Weigh In On Definium Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Virtu Financial LLC bought a new position in shares of Definium Therapeutics during the 3rd quarter worth $379,000. Blair William & Co. IL raised its holdings in shares of Definium Therapeutics by 43.6% in the third quarter. Blair William & Co. IL now owns 31,905 shares of the company's stock valued at $376,000 after acquiring an additional 9,687 shares in the last quarter. Cerity Partners LLC raised its holdings in shares of Definium Therapeutics by 2.4% in the second quarter. Cerity Partners LLC now owns 49,650 shares of the company's stock valued at $322,000 after acquiring an additional 1,165 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Definium Therapeutics by 5.1% in the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company's stock valued at $315,000 after acquiring an additional 2,342 shares in the last quarter. Finally, Sender Co & Partners Inc. purchased a new stake in Definium Therapeutics in the third quarter worth about $305,000. 27.91% of the stock is owned by institutional investors.

Definium Therapeutics Trading Down 3.1%

DFTX traded down $1.40 on Thursday, reaching $44.42. 524,620 shares of the company traded hands, compared to its average volume of 2,281,632. Definium Therapeutics has a one year low of $8.70 and a one year high of $49.70. The firm has a fifty day simple moving average of $41.19 and a two-hundred day simple moving average of $27.49. The company has a market cap of $5.97 billion, a P/E ratio of -12.95 and a beta of 2.23. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). As a group, equities research analysts expect that Definium Therapeutics will post -2.92 earnings per share for the current year.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source